H. Lundbeck A/S v Sandoz Pty Ltd; CNS Pharma Pty Ltd v Sandoz Pty Ltd [2022] HCA 4Date:Court:Judges:9 March 2022High...
High Court puts the brakes on damages recovery during patent term extension
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Vector Corrosion fails to cement entitlement claim
Vector Corrosion Technologies Limited v E-Chem Technologies Ltd [2022] FCA 188 Date:Court:Judge:9 March 2022Federal...
Pearce IP BioBlast w/e 11 March 2022
03 Mar 22 | US | FDA announced a new funding opportunity for the BsUFA III Regulatory Science Program to support...
Reminder – new .au domain names coming to Australia from 24 March 2022
Priority given to owners of corresponding Australian domain names in the .au race
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence...
Pearce IP BioBlast w/e 25 February 2022
18 Feb 22 | Celltrion released two data sets on the subcutaneous (SC) form of Remsima® (biosimilar infliximab)....
Why Preparedness Is So Pivotal
In this Boutique Lawyer Show podcast, Pearce IP’s CEO and Executive Naomi Pearce speaks candidly with Lawyers Weekly’s Jerome Doraisamy.
Nothing inventive in the electronic operation and configuration of fitness studios
F45 Training Pty Ltd v Body Fit Training Company Pty Ltd (No 2) [2022] FCA 96 Date:Court:Judge:15 February 2022Federal...
Pearce IP BioBlast 18 February 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and...
Interlocutory injunction to restrain further threats of patent infringement granted in car park scrap
UbiPark Pty Ltd v TMA Capital Australia Pty Ltd [2022] FCA 111 Date:Court:Judge:14 February 2022Federal Court of...
PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs)...
Pearce IP BioBlast w/e 11 February 2022
07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a...
Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
Bayer Pharma Aktiengesellschaft [2022] APO 7Date:Venue:Delegate:7 February 2022Australian Patent OfficeKeith...
Pearce IP BioBlast w/e 04 February 2022
01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of...
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP...
Pearce IP BioBlast® f/e 31 January 2022
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common...